{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'treatment at home in the morning at approximately the same time each day, as', 'directed by the clinic.', 'Safety/follow-up: A safety follow-up telephone contact or clinic visit (Visit 6)', 'will be conducted approximately 7 days after the participant completes all of the', 'protocol-defined procedures for Visit 5/End of Study (EOS) or, if applicable, the', 'Study Treatment Discontinuation Visit. A participant will be considered to have', 'completed the study when they have completed all phases of the study including', 'screening, run-in, the randomised treatment phase, and safety follow-up.', 'Participants who permanently discontinue double-blind study treatment are not required', 'to withdraw from the study. Participants who have permanently discontinued study', 'treatment and have not withdrawn consent are encouraged to continue in the study and', 'complete all remaining protocol specified clinic visits (see Section 8.1).', '5.2.', 'Number of Participants', 'Approximately 848 participants with advanced COPD will enter the run-in, in order to', 'randomise approximately 780 participants, in order to achieve an estimated 702 evaluble', 'participants. See Section 10 for further details.', 'Approximately 100 centres globally will be required to recruit the study.', '5.3.', 'Participant and Study Completion', 'A participant is considered to have completed the study if he/she has completed all', 'phases of the study including pre-screening, screening, run-in, the randomised treatment', 'phase and the safety follow-up.', 'The end of the study is defined as the date of the last scheduled procedure shown in the', 'Schedule of Activities (SoA) table (see Section 2) for the last participant in the trial', 'globally.', '5.4.', 'Scientific Rationale for Study Design', 'This study will use a multicenter, randomised, double-blind, double-dummy, parallel-', 'group design. A placebo arm is not included because the primary comparison of interest', 'is FF/UMEC/VI VS. tiotropium and it is not considered appropriate to include a placebo', 'arm in a study in patients with advanced COPD. Eligible participants must have been on', 'daily maintenance tiotropium for at least 3 months, and those randomised to tiotropium', 'will be essentially continuing their therapy prior to enrollment. Although LAMA', 'monotherapy in severe patients is not designated a preferred treatment option, it', 'continues to be listed as a treatment option for these patients (GOLD B or D) in the 2017', 'GOLD strategy document, and is commonly used in clinical practice. The 4-week run-in', 'period is necessary in order to assess participant compliance with and ability to use all of', 'the medications together and allow sufficient time for the results of screening', 'assessments to be returned to the site, in order to establish participant eligibility.', '40']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '5.5.', 'Dose Justification', 'The FF/UMEC/VI (100/62.5/25 mcg) dose was selected based on the doses that have', 'been licensed for COPD for the FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg) dual', 'combinations through extensive studies in the mono and dual therapy programmes. It is', 'the dose which is currently under regulatory review based on the Phase IIIa', 'FF/UMEC/VI registration programme.', 'The dose selected for tiotropium (18 mcg, once daily) is the dose licensed in the US for', 'use in COPD.', '6.', 'STUDY POPULATION', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', '1. Informed consent: capable of giving signed informed consent prior to study start', 'which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '2. Type of participant: Outpatient.', '3. Age: Participants 40 years of age or older at Screening (Visit 1).', '4. Gender: Male or female participants.', 'Female participants:', 'A female participant is eligible to participate if she is not pregnant, not breastfeeding, and', 'at least one of the following conditions applies:', 'Not a woman of childbearing potential (WOCBP)', 'OR', 'A WOCBP who agrees to follow the contraceptive guidance in', 'Appendix 3 during the treatment period and until the safety follow-up', 'contact after the last dose of study treatment.', '5. COPD Diagnosis: An established clinical history of COPD in accordance with the', 'definition by the American Thoracic Society/European Respiratory Society [Celli,', '2004].', '6.', 'Smoking History: Current or former cigarette smokers with a history of cigarette', 'smoking of >10 pack-years at Screening (Visit 1) [number of pack years = (number of', '41']\n\n###\n\n", "completion": "END"}